June 26, 2017 / 12:20 PM / 7 months ago

BRIEF-ImmunoGen presents data from Phase I study of IMGN779 in acute myeloid leukemia

June 26 (Reuters) - Immunogen Inc

* Immunogen inc- data from ongoing phase 1 study evaluating single agent imgn779 in patients with relapsed or refractory adult acute myeloid leukemia

* Immunogen inc- no increase in nature, frequency, or severity of any treatment-emergent adverse event has been reported with escalating doses in study

* Immunogen inc- no evidence of cumulative toxicity has been observed with repeated dosing in study

* Immunogen inc- no dlts have been observed through dose level seven, with reported adverse events consistent with underlying disease in study

* Immunogen inc- initial anti-leukemia activity was observed at dose levels six and seven in patients who failed intensive frontline therapy in study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below